Hormonal manipulation of lower urinary tract symptoms secondary to benign prostatic obstruction.

about

Hormonal manipulation of lower urinary tract symptoms secondary to benign prostatic obstruction.

Item

http://www.wikidata.org/entity/Q38205422

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Hormonal manipulation of lower ...... benign prostatic obstruction.

@en

type

Item

label

Hormonal manipulation of lower ...... benign prostatic obstruction.

@en

prefLabel

Hormonal manipulation of lower ...... benign prostatic obstruction.

@en

P1476

Hormonal manipulation of lower ...... benign prostatic obstruction.

@en

P2093

Adita Raja

http://www.w3.org/2001/XMLSchema#string

James N Armitage

http://www.w3.org/2001/XMLSchema#string

Satoshi Hori

http://www.w3.org/2001/XMLSchema#string

P2860

The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases

Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.

Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Alpha1-adrenoceptor subtypes and lower urinary tract symptoms

P304

189-193

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/0970-1591.126904

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24744519

http://www.w3.org/2001/XMLSchema#string

P932

3989822

http://www.w3.org/2001/XMLSchema#string